A Phase 3 interventional study of NVX-CoV2373 and SARS-CoV-2 rS antigen/Matrix-M Adjuvant in COVID-19, sponsored by Novavax. Completed at 5 sites in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-26.
Sponsored by Novavax · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 — none open to participants now, 2 under way, none of them phase 3. NVX-CoV2373 adjuvated lipid nanoparticle · COVID-19.
Among the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19, this one is the 17th largest by enrollment, is one of 4 that started in 2023, is one of 7 in phase 3, and was the 11th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →None of the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 is open now. The open studies under COVID-19, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 49 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 9 · Phase 4 5
First in 2020; this study’s year is marked. 4 started in 2023.
This study's enrollment of 147 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 997 across the 18 interventional studies. Of the 16 that completed or were terminated, 5 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 18 have an industry lead sponsor. The 7 most frequent:
Novavax is the lead sponsor of 47 studies on the registry; none are open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 7 (35%) have results posted.
21 studies in COVID-19 by Novavax: none open now, none under way, none of them phase 3. Of 18 finished, 4 (22%) have results posted.
Among the 21 studies in COVID-19 by Novavax, this one is the 17th largest by enrollment, is one of 4 that started in 2023, is one of 8 in phase 3, and was the 12th registered.
Novavax’s COVID-19 studies by the year they started, since 2020.
1 of the studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07861542SanofiStudy of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19 | 2026-11-26 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19, from their registry updates:
Among Novavax’s 21 in COVID-19:
This tab as a report to print or save as PDF → With an account.
This is an open-label Phase 3 study evaluating the immunogenicity and safety of Novavax vaccine(s) with Matrix-M™ adjuvant (ancestral strain NVX-CoV2373 and an alternative strain and/or multivalent Novavax vaccine) as booster doses following a series of primary and booster doses of authorized/approved mRNA vaccines followed by a single booster dose of NVX-CoV2373 in the Novavax 2019nCoV-307 study (NCT05463068).
This Phase 3 study investigates the immunogenicity and safety of Novavax's NVX-CoV2373 vaccine (including its Matrix-M adjuvant) as an additional booster dose for adults aged 18 to 49. Participants must have already received both their primary mRNA vaccine series and at least one booster dose of the same type. All participants were previously enrolled in Study 307 (NCT05463068), where they received either their primary mRNA vaccines with or without an additional mRNA booster, followed by a single NVX-CoV2373 booster.
The study involves up to 300 volunteers who will receive a single dose of the Novavax vaccine (5 micrograms of recombinant spike protein antigen and 50 micrograms of Matrix-M adjuvant) on Day 1.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be included in this study, each individual must satisfy all the following criteria:
Exclusion Criteria:
Participants meeting any of the following criteria will be excluded from the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1dose of NVX-COV2373 on Day 1
Biological: NVX-CoV2373
1dose of updated COVID-19 vaccine on Day 1
Biological: SARS-CoV-2 rS antigen/Matrix-M Adjuvant
1 intramuscular (IM) injection of 5 µg SARS-CoV-2 rS + 50 µg Matrix-M1 adjuvant (0.5 mL) given on Day 1
Also known as: SARS-CoV-2 rS/Matrix-M Adjuvant
1 intramuscular (IM) injection of 5 µg SARS-CoV-2 rS antigen+ 50 µg Matrix-M1 adjuvant (0.5 mL) given on Day 1
Also known as: Updated Novavax COVID-19 vaccine
Neutralizing Antibody (Nab) for SARS-CoV-2 Wildtype Virus (Wuhan) Responses Expressed as Geometric Mean Titers (GMT)
Neutralizing Antibody responses to ancestral strain Novavax vaccine (NVX-CoV2373) for the participants in the ancestral strain NVX-2373 group and NVX-CoV2540 group at Day 29
Time frame: Day 28
Neutralizing Antibody (Nab) for SARS-CoV-2 Wildtype Virus (Wuhan) Responses Expressed as Seroconversion Rate (SCR)
Neutralizing Antibody responses to ancestral strain Novavax vaccine (NVX-CoV2373) for the participants in the ancestral strain NVX-2373 group and NVX-CoV2540 group at Day 28
Time frame: Day 28
Serum Immunoglobulin G (IgG) ELISA Units to SARS-CoV-2 Spike Protein (Wuhan) Expressed as Geometric Mean ELISA Unit (GMEU)
Serum Immunoglobulin G (IgG) ELISA Units to SARS-CoV-2 Spike Protein (Wuhan) in Ancestral strain NVX-CoV2373 group and updated NVX Vaccine group at Day 28
Time frame: Day 28
Serum Immunoglobulin G (IgG) ELISA Units to SARS-CoV-2 Spike Protein (Wuhan) Expressed as SCR
Serum Immunoglobulin G (IgG) ELISA Units to SARS-CoV-2 Spike Protein (Wuhan) in Ancestral strain NVX-CoV2373 group and updated NVX Vaccine group at Day 28
Time frame: Day 28
Neutralizing Antibody Responses (Post-Booster) Expressed as GMT
Post Booster Neutralizing Antibody responses GMTs compared with post-first booster results from Study 307
Time frame: Day 0 and Day 28 of Study 307 and Study 312 (approximately 1 year from Day 0 of Study 307 and Day 0 of Study 312)
Serum IgG Antibody Levels (Post-Booster) Expressed as GMEU
Post Booster Serum IgG antibody levels expressed GMEUs compared with post-first booster results from Study 307
Time frame: Day 0 and Day 28 of Study 307 and Study 312 (approximately 1 year from Day 0 of Study 307 and Day 0 of Study 312)
Human Angiotensin-Converting Enzyme 2 (hACE2) Receptor Binding Inhibition Assay Expressed as SCR
hACE2 Receptor Binding Inhibition Assay the SARS-CoV-2 ancestral strain spike protein expressed as SCR at Day 28
Time frame: Day 28
Number of Participants Reported Solicited Local and Systemic Adverse Events (AEs)
Number of participants reported Solicited Local and Systemic Adverse Events (AEs) in the 7 days following study vaccination.
Time frame: Day 7
Number of Participants Reported With Medically Attended Adverse Events (MAAEs)
Number of participants reported with Medically Attended Adverse Events (MAAEs) through Day 180 after the vaccine dose.
Time frame: Day 180
Number of Participants Reported With Serious Adverse Events (SAEs)
Number of participants reported with Serious Adverse Events (SAEs) through Day 180 after the vaccine dose
Time frame: Day 1 to Day 180
Human Angiotensin-Converting Enzyme 2 (hACE2) Receptor Binding Inhibition Assay Expressed as SCR
hACE2 Receptor Binding Inhibition Assay to the NVX-CoV2540(Updated COVID-19 Vaccine) expressed as SCR at Day 28
Time frame: Day 28
| Milestone | NVX CoV2373 (Ancestral Strain) | NVX-CoV2540(Updated COVID-19 Vaccine) |
|---|---|---|
| Started | 104 | 43 |
| Completed | 101 | 42 |
| Not completed | 3 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 |
Neutralizing Antibody responses to ancestral strain Novavax vaccine (NVX-CoV2373) for the participants in the ancestral strain NVX-2373 group and NVX-CoV2540 group at Day 29
| titers | NVX CoV2373 (Ancestral Strain) | NVX-CoV2540(Updated COVID-19 Vaccine) |
|---|---|---|
| Date of 1st booster dose (Study 307) | 173.2 (123.0 to 243.8) | 159.5 (94.3 to 269.9) |
| 28 days after 1st booster dose (Study 307) | 396.6 (328.7 to 478.6) | 436.0 (305.6 to 622.2) |
| Date of 2nd booster dose (Study 312) | 306.4 (222.6 to 421.6) | 420.7 (282.5 to 626.6) |
| 28 days after 2nd booster dose (Study 312) | 393.2 (318.0 to 486.2) | 835.0 (597.1 to 1167.6) |
Neutralizing Antibody responses to ancestral strain Novavax vaccine (NVX-CoV2373) for the participants in the ancestral strain NVX-2373 group and NVX-CoV2540 group at Day 28
| participants | NVX CoV2373 (Ancestral Strain) | NVX-CoV2540(Updated COVID-19 Vaccine) |
|---|---|---|
| 28 days after 1st booster relative to date of 1st booster | 24 | 11 |
| 28 days after 2nd booster relative to date of 2nd booster | 21 | 11 |
| 28 days after 2nd booster relative to date of 1st booster | 31 | 22 |
Serum Immunoglobulin G (IgG) ELISA Units to SARS-CoV-2 Spike Protein (Wuhan) in Ancestral strain NVX-CoV2373 group and updated NVX Vaccine group at Day 28
| Elisa Units per mL | NVX CoV2373 (Ancestral Strain) | NVX-CoV2540(Updated COVID-19 Vaccine) |
|---|---|---|
| Date of 1st booster dose (Study 307) | 37822.4 (29104.7 to 49151.4) | 32446.8 (22453.4 to 46888.0) |
| 28 days after 1st booster dose (Study 307) | 93969.2 (79844.0 to 110593.4) | 93636.6 (69077.5 to 126927.1) |
| Date of 2nd booster dose (Study 312) | 67333.6 (54380.8 to 83371.6) | 71336.1 (50460.2 to 100848.6) |
| 28 days after 2nd booster dose (Study 312) | 162144.7 (136476.6 to 192640.4) | 203864.0 (148535.6 to 279801.8) |
Serum Immunoglobulin G (IgG) ELISA Units to SARS-CoV-2 Spike Protein (Wuhan) in Ancestral strain NVX-CoV2373 group and updated NVX Vaccine group at Day 28
| participants | NVX CoV2373 (Ancestral Strain) | NVX-CoV2540(Updated COVID-19 Vaccine) |
|---|---|---|
| 28 days after 1st booster relative to date of 1st booster | 22 | 11 |
| 28 days after 2nd booster relative to date of 2nd booster | 22 | 11 |
| 28 days after 2nd booster relative to date of 1st booster | 45 | 22 |
Post Booster Neutralizing Antibody responses GMTs compared with post-first booster results from Study 307
| geometric mean titer | NVX CoV2373 (Ancestral Strain) |
|---|---|
| Day 0 of 1st booster dose (Study 307) | 173.2 (123.0 to 243.8) |
| 28 days after 1st booster dose (Study 307) | 396.6 (328.7 to 478.6) |
| Day 0 of 2nd booster dose (Study 312) | 306.4 (222.6 to 421.6) |
| 28 days after 2nd booster dose (Study 312) | 393.2 (318.0 to 486.2) |
Post Booster Serum IgG antibody levels expressed GMEUs compared with post-first booster results from Study 307
| geometric mean Elisa Units | NVX CoV2373 (Ancestral Strain) |
|---|---|
| Day 0 of 1st booster dose (Study 307) | 37822.4 (29104.7 to 49151.4) |
| 28 days after 1st booster dose (Study 307) | 93969.2 (79844.0 to 110593.4) |
| Day 0 of 2nd booster dose (Study 312) | 67333.6 (54380.8 to 83371.6) |
| 28 days after 2nd booster dose (Study 312) | 162144.7 (136476.6 to 192640.4) |
hACE2 Receptor Binding Inhibition Assay the SARS-CoV-2 ancestral strain spike protein expressed as SCR at Day 28
| Percentage of participants | NVX CoV2373 (Ancestral Strain) |
|---|---|
| Human Angiotensin-Converting Enzyme 2 (hACE2) Receptor Binding Inhibition Assay Expressed as SCR | 12.6 (5.9 to 21.2) |
Number of participants reported Solicited Local and Systemic Adverse Events (AEs) in the 7 days following study vaccination.
| Participants | NVX CoV2373 (Ancestral Strain) | NVX-CoV2540(Updated COVID-19 Vaccine) |
|---|---|---|
| Any solicited local reaction | 68 | 31 |
| Pain | 48 | 18 |
| Tenderness | 62 | 29 |
| Redness | 7 | 1 |
| Swelling | 5 | 0 |
| Systemic reaction | 69 | 24 |
| Fever | 1 | 1 |
| Fatigue | 49 | 11 |
| Malaise | 31 | 5 |
| Muscle pain | 43 | 19 |
| Joint pain | 19 | 7 |
| Nausea/vomiting | 12 | 5 |
| Headache | 40 | 13 |
Number of participants reported with Medically Attended Adverse Events (MAAEs) through Day 180 after the vaccine dose.
| Participants | NVX CoV2373 (Ancestral Strain) | NVX-CoV2540(Updated COVID-19 Vaccine) |
|---|---|---|
| MAAEs | 5 | 1 |
| Severe MAAEs | 0 | 1 |
Number of participants reported with Serious Adverse Events (SAEs) through Day 180 after the vaccine dose
| Participants | NVX CoV2373 (Ancestral Strain) | NVX-CoV2540(Updated COVID-19 Vaccine) |
|---|---|---|
| Number of Participants Reported With Serious Adverse Events (SAEs) | 0 | 1 |
Post Booster Neutralizing Antibody responses GMTs compared with post-first booster results from Study 307
| geometric mean titer | NVX-CoV2540(Updated COVID-19 Vaccine) |
|---|---|
| Day 0 of 1st booster dose (Study 307) | 159.5 (94.3 to 269.9) |
| 28 days after 1st booster dose (Study 307) | 436.0 (305.6 to 622.2) |
| Day 0 of 2nd booster dose (Study 312) | 420.7 (282.5 to 626.6) |
| 28 days after 2nd booster dose (Study 312) | 835.0 (597.1 to 1167.6) |
Post Booster Serum IgG antibody levels expressed GMEUs compared with post-first booster results from Study 307
| geometric mean Elisa Units | NVX-CoV2540(Updated COVID-19 Vaccine) |
|---|---|
| Day 0 of 1st booster dose (Study 307) | 32446.8 (22453.4 to 46888.0) |
| 28 days after 1st booster dose (Study 307) | 93636.6 (69077.5 to 126927.1) |
| Day 0 of 2nd booster dose (Study 312) | 71336.1 (50460.2 to 100848.6) |
| 28 days after 2nd booster dose (Study 312) | 203864.0 (148535.6 to 279801.8) |
hACE2 Receptor Binding Inhibition Assay to the NVX-CoV2540(Updated COVID-19 Vaccine) expressed as SCR at Day 28
| participants | NVX-CoV2540(Updated COVID-19 Vaccine) |
|---|---|
| Human Angiotensin-Converting Enzyme 2 (hACE2) Receptor Binding Inhibition Assay Expressed as SCR | 1 |
Collected over 6 months. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NVX CoV2373 (Ancestral Strain) | 0/104 (0%) | 0/104 (0%) | 2/104 (1.9%) |
| NVX-CoV2540(Updated COVID-19 Vaccine) | 0/43 (0%) | 1/43 (2.3%) | 1/43 (2.3%) |
| Event | NVX CoV2373 (Ancestral Strain) | NVX-CoV2540(Updated COVID-19 Vaccine) |
|---|---|---|
| Post procedural haematomaInjury, poisoning and procedural complications | 0/104 | 1/43 |
| Event | NVX CoV2373 (Ancestral Strain) | NVX-CoV2540(Updated COVID-19 Vaccine) |
|---|---|---|
| LymphadenopathyBlood and lymphatic system disorders | 0/104 | 1/43 |
| COVID-19Infections and infestations | 2/104 | 0/43 |
Safety Analysis Set
| Age, Continuous(years) | NVX CoV2373 (Ancestral Strain) | NVX-CoV2540(Updated COVID-19 Vaccine) | Total |
|---|---|---|---|
| Mean | 38.3 ± 7.97 | 37.2 ± 9.20 | 37.75 ± 8.58 |
| Sex: Female, Male(Participants) | NVX CoV2373 (Ancestral Strain) | NVX-CoV2540(Updated COVID-19 Vaccine) | Total |
|---|---|---|---|
| Female | 63 | 23 | 86 |
| Male | 41 | 20 | 61 |
| Ethnicity (NIH/OMB)(Participants) | NVX CoV2373 (Ancestral Strain) | NVX-CoV2540(Updated COVID-19 Vaccine) | Total |
|---|---|---|---|
| Hispanic or Latino | 12 | 6 | 18 |
| Not Hispanic or Latino | 92 | 36 | 128 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | NVX CoV2373 (Ancestral Strain) | NVX-CoV2540(Updated COVID-19 Vaccine) | Total |
|---|---|---|---|
| White | 73 | 25 | 98 |
| Black or African American | 23 | 15 | 38 |
| Asian | 3 | 3 | 6 |
| Other | 3 | 0 | 3 |
| Not Reported/Specified | 2 | 0 | 2 |
| Time between first dose of previous NVX vaccine at Study 307 and Day 1 dose of Study 312(days) | NVX CoV2373 (Ancestral Strain) | NVX-CoV2540(Updated COVID-19 Vaccine) | Total |
|---|---|---|---|
| Mean | 265.0 ± 25.92 | 311.0 ± 1.85 | 288 ± 27.77 |
| PCR, n (%)(Participants) | NVX CoV2373 (Ancestral Strain) | NVX-CoV2540(Updated COVID-19 Vaccine) | Total |
|---|---|---|---|
| Positive | 1 | 0 | 1 |
| Negative | 98 | 42 | 140 |
| Missing | 5 | 1 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2023 to primary completion in Nov 2023, 7 months.
Results were first posted in Jun 2025, 1 year 7 months after primary completion. A results delay was requested in Feb 2024.
Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 7 months is below that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: NVX-CoV2373 adjuvated lipid nanoparticle